INTRODUCTION
A study by Curtis et al. [14] evaluated the overall safety of TCZ in patients with RA using TCZ data from a large postmarketing safety database (cutoff date July 29, 2011) and clinical trials (cutoff date April 1, 2011) and aTNF comparator data from a US external healthcare insurance claims database (January 1, 2010 to June 30, 2014) and published literature. The overall risk of serious adverse events (SAEs) associated with TCZ treatment was not greater than with aTNF agents.
It was also shown in the analyses by Curtis et al. [14] that the rates of certain TCZ-related safety events of special interest-including serious hepatic events, serious gastrointestinal (GI) events, serious myocardial infarctions, serious strokes, and cardiac deaths-were similar to corresponding rates from the aTNF comparator population. Of particular interest, GI perforation (GIP) is a rare but serious adverse drug reaction that has been observed in relation to medications for RA and is also listed under the warnings and precautions of the TCZ prescribing information. Risk factors for GIP in patients with RA include a history of diverticulitis, advanced age, use of glucocorticoids and/or nonsteroidal anti-inflammatory drugs (NSAIDs), and smoking [15] [16] [17] [18] . In the TCZ safety analysis, The objective of this report was to update the available GIP safety information associated with TCZ administration from multiple data sources (clinical trials database, postmarketing, and real-world administrative claims) and to examine whether the frequency in risk of GIP has changed over time. In addition, the incidence of GIP from a single real-world healthcare claims database was compared between patients with RA who received TCZ, aTNF agents, or abatacept. 
METHODS

Clinical Trial Database Population
The clinical trial database population included patients with RA from the 5 core TCZ-IV Phase III   RA clinical trials (OPTION, RADIATE, TOWARD,  AMBITION, and LITHE; ClinicalTrials.gov   identifiers:  NCT00106548,  NCT00106522,   NCT00106574,  NCT00109408 , and NCT00106535, respectively) [5-9], the TCZ-IV RA lipid study (MEASURE) [19] , the TCZ-IV in early RA study (FUNCTION; ClinicalTrials.gov identifier: NCT01007435) [13] , the TCZ-IV monotherapy study (ADACTA; ClinicalTrials.gov identifier: NCT01119859) [20] , and the all-exposure data from the TCZ-IV long-term extension RA studies. The data cutoff was December 2014, after the TCZ-IV long-term extension studies were completed.
Global Postmarketing Safety Database Population
Reporting rates of GIP events in the global postmarketing setting were based on AEs occurring in TCZ-treated patients recorded in the company postmarketing safety database up to April 10, 2015. This database records information on all spontaneously reported cases (serious and non-serious) in which TCZ is per default considered ''suspect'' and all non-interventional program/ non-interventional study cases (serious and non-serious) in which TCZ is considered ''suspect''; reports from the literature are also included. All AEs, regardless of whether the reporter assessed it to be causally related to TCZ, were included in this analysis. 
Classification of GIPs in the Clinical
Safety Analysis in the Healthcare
Insurance Claims Database Population
Two definitions of GIP were evaluated in the healthcare claims databases to generate a best estimate of the range of the incidence rates of true GIP [21] . The first definition (sensitive) included any inpatient admissions with evidence of perforation based on: (1) This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
TCZ-IV Clinical Trial Database Population
The TCZ-IV all-exposure RA clinical trial population includes data from 5185 patients who received C1 dose of TCZ-IV and includes all data from the time of first TCZ dose, representing 17,905.9 PYs of exposure (Table 1) . From the SMQ ''GIP-narrow'' search, 70 events were reported in 53 patients.
Of these, 34 events in 31 patients were adjudicated as GIPs, for an incidence rate (95% CI) of 1.9 (1.3-2.7) events per 1000 PYs. Of these 34 events, 9 occurred in 9 patients (29%) with a history of diverticular disease, gastritis, or ulcer, and 16 occurred in 16 patients (52%) with a diagnosis of diverticular disease at the time of surgery or during the course of the clinical trial.
There was no increase in number of GIPs with increased TCZ exposure or duration of study ( was comparable with rates observed at earlier time points. The majority of GIPs (85%) in the TCZ-IV all-exposure population occurred in the lower GI tract.
In the all-exposure TCZ-IV clinical trial population, baseline demographic data were comparable between the overall population and patients who experienced a GIP ( Table 2 ). The mean (standard deviation) age was greater for patients who experienced an adjudicated GIP than for the overall population: 58.5 (10.6) years compared with 51.7 (12.8) years-a trend with age being a risk factor for GIP [17] . The proportion of patients with prior exposure to aTNF agents was 22.6% for those who experienced an adjudicated GIP compared with 17.0% for the overall population. Of patients with an adjudicated GIP, 17.9% had a history of smoking compared with 18.0% of patients in the overall population.
SC-administered TCZ has been studied in 2
RA clinical trials, with a total of 2039 PYs of exposure (n = 1374). The incidence rate of GIP events in the TCZ-SC all-exposure population was slightly lower (1.5 per 1000 PYs) than in the 
TCZ Global Postmarketing Safety Database
The SMQ ''GIP-narrow'' search retrieved 449 events in 437 patients from the global postmarketing safety database for which a causal or temporal association between GIPs and TCZ could not be excluded, for an overall reporting rate (95% CI) of 1. AE adverse event, aTNF anti-tumor necrosis factor, DMARD disease-modifying antirheumatic drug, GIP gastrointestinal perforation, IV intravenous, RF rheumatoid factor, SMQ Standard Medical Dictionary for Regulatory Activity Query, TCZ tocilizumab a Retrieved cases were adjudicated for evidence of perforation within the GI system: cases reporting abscess or peritonitis with no evidence of perforation were not considered to be GIP events b Percentages were based on patients with nonmissing data. In the overall group, 716 of 3986 patients were smokers; in the adjudicated GIP group, 5 of 28 patients were smokers History of diverticulitis, n 7 perforation accompanied by both diverticulosis and diverticulitis).
Of 437 patients with GIP retrieved from the postmarketing safety database, 21 (4.8%) had fatal outcomes. In 18 of these 21 patients, GIP was reported as the underlying event of death. Of these 18 patients, perforation occurred in the lower GI tract in 14 patients, the upper GI tract in 2 patients, and unspecified locations in 2 patients. In the remaining 3 patients, the causes of death were peritonitis secondary to perforation of colonic diverticulitis, perforative peritonitis and disseminated intravascular coagulation, and unrelated causes.
US Insurance Claims Database
A total of 58,334 patients with RA treated with an aTNF, abatacept, or TCZ who met the eligibility criteria for analysis were identified in the healthcare claims. Patients were followed for a mean of 535 days. Overall, approximately 50% of patients had no evidence of prior exposure to a qualifying biologic DMARD. However, of the patients who initiated TCZ, most (88%) had prior biologic exposure; therefore, the safety analysis reported in detail here focused only on the population of patients who had received C1 prior biologic DMARD.
Of the patients with prior biologic exposure, the mean age was similar for those who received an aTNF, abatacept, or TCZ (52.2, 54.4, and 54.1 years, respectively; Table 4 ). Patients who received TCZ tended to have received more prior biologics; 27.3% of patients in the TCZ group received C3 prior biologics compared with 11.4% in the abatacept group and 7.8% in the aTNF group. Similar proportions of patients across the groups had exposure to prescription NSAIDs (43.6%, 41.0%, and 41.9% for the aTNF, abatacept, and TCZ groups, respectively). Mean exposure to oral glucocorticoids was also similar across groups.
Of the patients with prior biologic exposure, there were 21 GIPs (10 from the aTNF group, 5 from the abatacept group, and 6 from the TCZ group) per the specific definition and 31 (14 from the aTNF group, 8 from the abatacept group, and 9 from the TCZ group) per the sensitive definition (Table 5 ). The GIP incidence rate (95% CI) per the specific definition for the TCZ group was 1.8 (0.7-4.0) per 1000 PYs compared with 0.6 (0.3-1.2) and 0.8 (0.3-2.0) History of GIP, n (%) 3 (1.5)
CI confidence interval, GIP gastrointestinal perforation, NSAID nonsteroidal anti-inflammatory drug, PY patient-year, TCZ tocilizumab a As defined in each row b Sufficient information for a comprehensive analysis was available for 298 GIP events reported in 295 patients. For 60 of these patients, the site of GIP was unspecified. Some patients had more than 1 site of perforation: 2 patients had both a lower GIP and an unspecified site of perforation; in 1 patient, only 1 GIP was reported, although in the case details both upper and lower GIPs were identified-these have been included as both upper and lower GIPs, respectively c In one case, both medical history and concomitant condition of diverticular disease were reported d In these 91 patients, the qualifying event was observed at the time of GIP diagnosis and was either diverticular perforation or the GIP was associated with diverticular disease (diverticulitis, diverticulum, diverticula)
per 1000 PYs for the aTNF and abatacept groups, respectively. According to the specific definition, the incidence rates (95% CI) for the ABA abatacept, ADA adalimumab, aTNF anti-tumor necrosis factor, CCI Charlson Comorbidities Index, csDMARD conventional synthetic disease-modifying antirheumatic drug, ETA etanercept, IFX infliximab, MOA mechanism of action, NSAID nonsteroidal anti-inflammatory drug, TCZ tocilizumab a These individual aTNF agents were selected to present because they represent the largest cohorts. The multivariable model used all five aTNF agents pooled vs. TCZ
The unadjusted absolute rate differences (95% CIs) between the TCZ and aTNF groups for all GIPs were 1.2 (-0.3 to 2.5) and 1.9 (0.0-3.7) per 1000 PYs per the specific and sensitive definitions, respectively. For lower GIPs, the unadjusted absolute rate differences were 1.2 (-0.2 to 2.5) and 1.8 (0.1-3.6) per 1000 PYs per the specific and sensitive definitions, respectively. aTNF anti-tumor necrosis factor, CI confidence interval, GIP gastrointestinal perforation, ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification, IR incidence rate, MOA mechanism of action, PY patient-year a Incidence rates per 1000 PYs b The specific definition included only inpatient admissions with evidence of perforation based on the presence of the word perforation in ICD-9-CM diagnosis descriptions for esophageal rupture; gastric, duodenal, peptic, or gastrojejunal ulcers; and unspecified GIP. Cases of appendicitis, diverticulitis, diverticulosis, or ischemic colitis associated with surgical GI procedures were not included c The sensitive definition included any inpatient admissions with evidence of perforation based on (1) the presence of the word perforation in the following ICD-9-CM diagnosis descriptions: esophageal rupture; gastric, duodenal, peptic, or gastrojejunal ulcers; appendicitis; and GI perforation of an unspecific location in the large intestine or (2) an ICD-9-CM diagnosis of diverticulitis, diverticulosis, or ischemic colitis plus a Current Procedural Terminology code for suture or resection of the small or large intestine exposure than for TCZ), the GIP incidence rate was similar to the overall aTNF-exposed population.
DISCUSSION
The incidence rates of GIP events in patients treated with TCZ are reported here from three 
